Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trial
Authors' conclusion
This is the first study reporting disparate MTX-PG accumulation profiles in RBCs versus PBMCs in newly diagnosed patients with RA during 6 months oral or subcutaneous MTX administration.
Study context
- Population
- Newly diagnosed patients with rheumatoid arthritis (RA) (mean age 58.5 years, 77% female)
- Participants
- 43 participants
- Exposure
- Oral vs subcutaneous MTX; Methotrexate polyglutamate (MTX-PG) accumulation in peripheral blood mononuclear cells (PBMCs) vs red blood cells (RBCs)
- Outcome
- Pharmacokinetics of MTX-PG1-6 accumulation in RBCs and PBMCs
- Follow-up
- 1, 2, 3 and 6 months
Methodological detailsrandomised to oral or subcutaneous MTX
- Randomised to oral or subcutaneous MTX
Main finding
As reported in the abstract
MTX-PG accumulation in PBMCs vs RBCs
- Intracellular MTX-PG accumulation in PBMCs 10-fold to 20-fold higher than in RBCs at all time points, regardless of administration route
- p<0.001
Observational data: associations, not effects.
Original publication
Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trial. Ann Rheum Dis. Published 21 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →